Clinical Trials Browser

NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1 Active not recruiting

48 enrolled

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT03537690 2026-04-29

FID-007 in Treating Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

50 enrolled

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT03479268 2026-04-27

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

18 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT01165333 2026-03-16

CILENT

Phase 1 Completed

32 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Phase 1 Completed

50 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Phase 1 Completed

26 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT03552471 2025-02-13

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1 Completed

25 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

29 enrolled

Lymphoid

Hodgkin Disease

NCT03502577 2024-01-08

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Phase 1 Terminated

19 enrolled

Plasma cell

Multiple Myeloma

NCT03552796 2023-06-26

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Phase 1 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT03756818 2023-02-28

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

52 enrolled

Gynecologic

Ovarian Neoplasms

NCT03291938 2020-11-24

IACS-010759 in Advanced Cancers

Phase 1 Completed

29 enrolled

BreastGastrointestinalLymphoid

Lymphoma, Neoplasm Metastasis, Pancreatic Neoplasms, Triple Negative Breast Neoplasms